Skip to main content
SpringerLink
Log in

Effects of Hormones

  • Chapter
Diagnosis of Endometrial Biopsies and Curettings

Women receive hormone preparations for a variety of reasons, including birth control and treatment for dysfunctional uterine bleeding, perimenopausal and postmenopausal symptoms, endometriosis, endometrial hyperplasia and carcinoma, breast carcinoma, and certain types of infertility. Usually the exogenous hormone is some form of progestin, but estrogenic and even androgenic hormones are used for some disorders. The endometrium shows the effects of these hormones.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility, 6th ed. Baltimore: Lippincott Williams & Wilkins, 1999.

    Google Scholar 

  2. Schiff I. Menopause. In: Kistner RW, ed. Gynecology: Principles and practice. Chicago: Year Book Medical Publishers; 1986: 565–582.

    Google Scholar 

  3. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996; 275:370–375.

    Google Scholar 

  4. Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in postmenopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas 1997; 26:219–226.

    Article  PubMed  CAS  Google Scholar 

  5. Gomes AM, Baracat EC, Simoes MJ, Haidar MA, Focchi GR, Evencio-Neto J, et al. Morphologic and morphometric aspects of the endometrium of postmenopausal women before and after cyclic oestrogen replacement treatment. Eur J Obstet Gynecol Reprod Biol 1997; 74:79–82.

    Article  PubMed  CAS  Google Scholar 

  6. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016–1037.

    PubMed  CAS  Google Scholar 

  7. Whitehead MI, Fraser D. The effects of estrogens and progestogens on the endometrium. Obstet Gynecol Clin North Am 1987; 14:299–320.

    PubMed  CAS  Google Scholar 

  8. Ober W. Effects of oral and intrauterine administration of contraceptives on the uterus. Hum Pathol 1977; 8:513–527.

    Article  PubMed  CAS  Google Scholar 

  9. Dallenbach-Hellweg G. Histopathology of the endometrium, 4th ed. New York: Springer-Verlag; 1987.

    Google Scholar 

  10. Sherman ME, Mazur MT, Kurman RJ. Benign diseases of the endometrium. In: Kurman RJ, ed. Blaustein’s pathology of the female genital tract. 5th ed. New York: Springer-Verlag; 2002: 421–466.

    Google Scholar 

  11. Deligdisch L. Effects of hormone therapy on the endometrium. Mod Pathol 1993; 6:94–106.

    PubMed  CAS  Google Scholar 

  12. Hesla J, Kurman R, Rock J. Histologic effects of oral contraceptives on the uterine corpus and cervix. Sem Reprod Endocrinol 1989; 7:213–219.

    Article  Google Scholar 

  13. Deligdisch L. Hormonal pathology of the endometrium. Mod Pathol 2000; 13:285–294.

    Article  PubMed  CAS  Google Scholar 

  14. Yuzpe AA, Thurlow HJ, Ramzy I, Leyshon JI. Post coital contraception—A pilot study. J Reprod Med 1974; 13:53–58.

    PubMed  CAS  Google Scholar 

  15. Raymond EG, Lovely LP, Chen-Mok M, Seppala M, Kurman RJ, Lessey BA. Effect of the Yuzpe regimen of emergency contraception on markers of endometrial receptivity. Hum Reprod 2000; 15:2351–2355.

    Article  PubMed  CAS  Google Scholar 

  16. Swahn ML, Westlund P, Johannisson E, Bygdeman M. Effect of post-coital contraceptive methods on the endometrium and the menstrual cycle. Acta Obstet Gynecol Scand 1996; 75:738–744.

    Article  PubMed  CAS  Google Scholar 

  17. Miranda MC, Mazur MT. Endometrial squamous metaplasia. An unusual response to progestin therapy of hyperplasia. Arch Pathol Lab Med 1995; 119:458–460.

    PubMed  CAS  Google Scholar 

  18. Dockerty MB, Smith RA, Symmonds RE. Pseudomalignant endometrial changes induced by administration of new synthetic progestins. Staff Meetings of the Mayo Clinic 1959; 34:321–328.

    CAS  Google Scholar 

  19. Cruz-Aquino M, Shenker L, Blaustein A. Pseudosarcoma of the endometrium. Obstet Gynecol 1967; 29:93–96.

    PubMed  CAS  Google Scholar 

  20. Clement PB, Scully RE. Idiopathic postmenopausal decidual reaction of the endometrium. Int J Gynecol Pathol 1988; 7:152–161.

    PubMed  CAS  Google Scholar 

  21. Iezzoni JC, Mills SE. Nonneoplastic endometrial signet-ring cells. Vacuolated decidual cells and stromal histiocytes mimicking adenocarcinoma. Am J Clin Pathol 2001; 115:249–255.

    Article  PubMed  CAS  Google Scholar 

  22. Bernardini L, Araujo FE, Balmaceda JP. A case of permanent endometrial hypotrophy after long-term use of oral contraceptives. Hum Reprod 1993; 8:543–546.

    PubMed  CAS  Google Scholar 

  23. Gelfand MM, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: Effects on the endometrium. Obstet Gynecol 1989; 74:398–402.

    PubMed  CAS  Google Scholar 

  24. Mishell DRJ. Menopause. In: Stenchever MA, Droegemueller W, Herbst AL, Mishell DRJ, eds. Comprehensive gynecology. 4th ed. St. Louis: Mosby: 2001: 1217–1258.

    Google Scholar 

  25. Feeley KM, Wells M. Hormone replacement therapy and the endometrium. J Clin Pathol 2001; 54:435–440.

    Article  PubMed  CAS  Google Scholar 

  26. Byrjalsen I, Thormann L, Meinecke B, Riis BJ, Christiansen C. Sequential estrogen and progestogen therapy—Assessment of progestational effects on the postmenopausal endometrium. Obstet Gynecol 1992; 79: 523–528.

    PubMed  CAS  Google Scholar 

  27. Carranza-Lira S, Martinez-Chequer JC, Santa Rita MT, Ortiz dlP, Perez Y, Fernandez RL. Endometrial changes according to hormone replacement therapy schedule. Menopause 1998; 5:86–89.

    PubMed  CAS  Google Scholar 

  28. Habiba MA, Bell SC, Al Azzawi F. Endometrial responses to hormone replacement therapy: histological features compared with those of late luteal phase endometrium. Hum Reprod 1998; 13:1674–1682.

    Article  PubMed  CAS  Google Scholar 

  29. Magos AL, Brewster E, Singh R, O’Dowd T, Brincat M. Amenorrhea and endometrial atrophy with continuous oral estrogens and progestogen therapy in post-menopausal women. Obstet Gynecol 1985; 65:496–499.

    PubMed  CAS  Google Scholar 

  30. Hillard TC, Siddle NC, Whitehead MI, Fraser DI, Prysedavies J. Continuous combined conjugated equine estrogen-progestogen therapy—effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol 1992; 167:1–7.

    PubMed  CAS  Google Scholar 

  31. Piegsa K, Calder A, Davis JA, McKay-Hart D, Wells M, Bryden F. Endometrial status in postmenopausal women on long-term continuous combined hormone replacement therapy (Kliofem). A comparative study of endometrial biopsy, outpatient hysteroscopy and transvaginal ultrasound. Eur J Obstet Gynecol Reprod Biol 1997; 72:175–180.

    Article  PubMed  CAS  Google Scholar 

  32. Sturdee DW. Endometrial morphology and bleeding patterns as a function of progestogen supplementation. Int J Fertil Menopausal Stud 1996; 41:22–28.

    PubMed  CAS  Google Scholar 

  33. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: A critical review. Obstet Gynecol 1995; 86:306–316.

    Article  PubMed  CAS  Google Scholar 

  34. Moyer DL, Delignieres B, Driguez P, Pez JP. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement—influence of bleeding pattern and secretory changes. Fertil Steril 1993; 59:992–997.

    PubMed  CAS  Google Scholar 

  35. Bjarnason K, Cerin A, Lindgren R, Weber T. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas 1999; 32:161–170.

    Article  PubMed  CAS  Google Scholar 

  36. Sturdee DW, Ulrich LG, Barlow DH, Wells M, Campbell MJ, Vessey MP, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. Br J Obstet Gynaecol 2000; 107:1392–1400.

    CAS  Google Scholar 

  37. Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high-and low-dose estrogen-progestin regimens. Osteoporos Int 2000; 11:929–937.

    Article  PubMed  CAS  Google Scholar 

  38. Nand SL, Webster MA, Baber R, O’Connor V. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. Obstet Gynecol 1998; 91(5 Pt 1):678–684.

    Article  PubMed  CAS  Google Scholar 

  39. Oosterbaan HP, van Buuren AH, Schram JH, van Kempen PJ, Ubachs JM, van Leusden HA, et al. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas 1995; 21:211–219.

    Article  PubMed  CAS  Google Scholar 

  40. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76:969–973.

    Article  PubMed  CAS  Google Scholar 

  41. Kurman RJ, Felix JC, Archer DF, Nanavati N, Arce J, Moyer DL. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000; 96:373–379.

    Article  PubMed  CAS  Google Scholar 

  42. Te Linde RW, Henriksen E. Decidualike changes in the endometrium without pregnancy. Am J Obstet Gynecol 1940; 39:733–749.

    Google Scholar 

  43. Dallenbach-Hellweg G, Hohagen F. On the problem of premature decidualization induced by the embryo transfer. Lab Investi 1985; 52:17A (Abstr).

    Google Scholar 

  44. Tamada T, Okagaki T, Maruyama M, Matsumoto S. Endometrial histology associated with an intrauterine contraceptive device. Am J Obstet Gynecol 1967; 98:811–817.

    PubMed  CAS  Google Scholar 

  45. Bonney WA, Glasser SR, Clewe TH, Noyes RW, Cooper CL. Endometrial response to the intrauterine device. Am J Obstet Gynecol 1966; 96:101–113.

    PubMed  Google Scholar 

  46. Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol 2002; 101:58–63.

    Article  PubMed  CAS  Google Scholar 

  47. Goldstein SR. The effect of SERMs on the endometrium. Ann NY Acad Sci 2001; 949:237–242.

    Article  PubMed  CAS  Google Scholar 

  48. Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJD, Cordoba M, et al. Timedependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol 1996; 15:152–157.

    PubMed  CAS  Google Scholar 

  49. Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Hudis C, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy. J Clin Oncol 2000; 18:3459–3463.

    PubMed  CAS  Google Scholar 

  50. Cohen I, Perel E, Flex D, Tepper R, Altaras MM, Cordoba M, et al. Endometrial pathology in postmenopausal tamoxifen treatment: Comparison between gynaecologically symptomatic and asymptomatic breast cancer patients. J Clin Pathol 1999; 52:278–282.

    Article  PubMed  CAS  Google Scholar 

  51. Marchesoni D, Driul L, Fabiani G, Di Loreto C, Cataldi P, Mozzanega B. Endometrial histologic changes in post-menopausal breast cancer patients using tamoxifen. Int J Gynaecol Obstet 2001; 75:257–262.

    Article  PubMed  CAS  Google Scholar 

  52. Seoud M, Shamseddine A, Khalil A, Salem Z, Saghir N, Bikhazi K, et al. Tamoxifen and endometrial pathologies: A prospective study. Gynecol Oncol 1999; 75:15–19.

    Article  PubMed  CAS  Google Scholar 

  53. Ozsener S, Ozaran A, Itil I, Dikmen Y. Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen. Eur J Gynaecol Oncol 1998; 19:580–583.

    PubMed  CAS  Google Scholar 

  54. Cohen I, Figer A, Altaras MM, Tepper R, Shapira J, Cordoba M, et al. Common endometrial decidual reaction in postmenopausal breast cancer patients treated with tamoxifen and progestogens. Int J Gynecol Pathol 1996; 15:17–22.

    PubMed  CAS  Google Scholar 

  55. Cohen I, Shapira J, Altaras M, Cordoba M, Rosen D, Beyth Y. Endometrial decidual changes in a postmenopausal woman treated with tamoxifen and megestrol acetate. Br J Obstet Gynaecol 1992; 99:773–774.

    PubMed  CAS  Google Scholar 

  56. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83:1013–1017.

    Article  PubMed  CAS  Google Scholar 

  57. Segna RA, Dottino RR, Deligdisch L, Cohen CJ. Tamoxifen and endometrial cancer. Mt Sinai J Med 1992; 59:416–418.

    PubMed  CAS  Google Scholar 

  58. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11:485–490.

    PubMed  CAS  Google Scholar 

  59. Gusberg SB. Tamoxifen for breast cancer: Associated endometrial cancer. Cancer 1990; 65:1463–1464.

    Article  PubMed  CAS  Google Scholar 

  60. Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T, Askevgren J, et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989; 1(8636):117–120.

    Article  PubMed  CAS  Google Scholar 

  61. Seoud MA-F, Johns J, Weed JCJ. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 1993; 82:165–169.

    PubMed  CAS  Google Scholar 

  62. Carcangiu ML. Uterine pathology in tamoxifen-treated patients with breast cancer. Anat Pathol 1997; 2:53–70.

    PubMed  CAS  Google Scholar 

  63. Dallenbach-Hellweg G, Schmidt D, Hellberg P, Bourne T, Kreuzwieser E, Doren M, et al. The endometrium in breast cancer patients on tamoxifen. Arch Gynecol Obstet 2000; 263:170–177.

    Article  PubMed  CAS  Google Scholar 

  64. Silva EG, Tornos CS, Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: The effects of tamoxifen. Int J Gynecol Pathol 1994; 13:248–258.

    Article  PubMed  CAS  Google Scholar 

  65. Deligdisch L, Kalir T, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000; 78:181–186.

    Article  PubMed  CAS  Google Scholar 

  66. Cohen I, Azaria R, Fishman A, Tepper R, Shapira J, Beyth Y. Endometrial cancers in postmenopausal breast cancer patients with tamoxifen treatment. Int J Gynecol Pathol 1999; 18:304–309.

    Article  PubMed  CAS  Google Scholar 

  67. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371–1388.

    Article  PubMed  CAS  Google Scholar 

  68. Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20:2758–2760.

    PubMed  Google Scholar 

  69. Clement PB, Oliva E, Young RH. Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: A report of six cases and a review of tamoxifen-associated endometrial lesions. Int J Gynecol Pathol 1996; 15:222–229.

    Article  PubMed  CAS  Google Scholar 

  70. McCluggage WG, Abdulkader M, Price JH, Kelehan P, Hamilton S, Beattie J, et al. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. Int J Gynecol Cancer 2000; 10:280–284.

    Article  PubMed  Google Scholar 

  71. Nuovo MA, Nuovo GJ, McCaffrey FM, Levine RU, Barron B, Winkler B. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989; 8:125–131.

    Article  PubMed  CAS  Google Scholar 

  72. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 1992; 79:111–116.

    PubMed  CAS  Google Scholar 

  73. Lahti E, Blanco G, Kauppila A, Apajasarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81:660–664.

    PubMed  CAS  Google Scholar 

  74. Kennedy MM, Baigrie CF, Manek S. Tamoxifen and the endometrium: Review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology. Int J Gynecol Pathol 1999; 18:130–137.

    Article  PubMed  CAS  Google Scholar 

  75. Cohen I, Azaria R, Bernheim J, Shapira J, Beyth Y. Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen. Cancer 2001; 92:1151–1155.

    Article  PubMed  CAS  Google Scholar 

  76. Liedman R, Lindahl B, Andolf E, Willen R, Ingvar C, Ranstam J. Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res 2000; 20:4889–4891.

    PubMed  CAS  Google Scholar 

  77. Schlesinger C, Kamoi S, Ascher SM, Kendell M, Lage JM, Silverberg SG. Endometrial polyps: A comparison study of patients receiving tamoxifen with two control groups. Int J Gynecol Pathol 1998; 17:302–311.

    Article  PubMed  CAS  Google Scholar 

  78. Biron-Shental T, Tepper R, Fishman A, Shapira J, Cohen I. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol 2003; 90:382–386.

    Article  PubMed  CAS  Google Scholar 

  79. Cohen I, Bernheim J, Azaria R, Tepper R, Sharony R, Beyth Y. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 1999; 75:136–141.

    Article  PubMed  CAS  Google Scholar 

  80. McCluggage WG, Sumathi VP, McManus DT. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: Report of 5 cases, including 2 associated with tamoxifen therapy. Hum Pathol 2003; 34:939–943.

    Article  PubMed  CAS  Google Scholar 

  81. Houghton JP, Ioffe OB, Silverberg SG, McGrady B, McCluggage WG. Metastatic breast lobular carcinoma involving tamoxifenassociated endometrial polyps: Report of two cases and review of tamoxifen-associated polypoid uterine lesions. Mod Pathol 2003; 16:395–398.

    Article  PubMed  CAS  Google Scholar 

  82. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281:2189–2197.

    Article  PubMed  CAS  Google Scholar 

  83. Goldstein SR. Update on raloxifene to prevent endometrial-breast cancer. Eur J Cancer 2000; 36Suppl 4:S54–S56.

    Article  PubMed  CAS  Google Scholar 

  84. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997; 177:1458–1464.

    Article  PubMed  CAS  Google Scholar 

  85. Davies GC, Huster WJ, Shen W, Mitlak B, Plouffe L, Jr, Shah A, et al. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 1999; 6:188–195.

    PubMed  CAS  Google Scholar 

  86. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641–1647.

    Article  PubMed  CAS  Google Scholar 

  87. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000; 95:95–103.

    Article  PubMed  CAS  Google Scholar 

  88. Wentz AC. Endometrial biopsy in the evaluation of infertility. Fertil Steril 1980; 33:121–124.

    PubMed  CAS  Google Scholar 

  89. Keenan JA, Herbert CM, Bush JR, Wentz AC. Diagnosis and management of out-of-phase endometrial biopsies among patients receiving clomiphene citrate for ovulation induction. Fertil Steril 1989; 51:964–967.

    PubMed  CAS  Google Scholar 

  90. Cook CL, Schroeder JA, Yussman MA, Sanfilippo JS. Induction of luteal phase defect with clomiphene citrate. Am J Obstet Gynecol 1984; 149:613–616.

    PubMed  CAS  Google Scholar 

  91. Van Hall EV, Mastboom JL. Luteal phase insufficiency in patients treated with clomiphene. Am J Obstet Gynecol 1969; 103:165–171.

    PubMed  Google Scholar 

  92. Yeko TR, Bardawil WA, Nicosia SM, Dawood MY, Maroulis GB. Histology of midluteal corpus luteum and endometrium from clomiphene citrate-induced cycles. Fertil Steril 1992; 57:28–32.

    PubMed  CAS  Google Scholar 

  93. Hecht BR, Bardawil WA, Khan-Dawood FS, Dawood MY. Luteal insufficiency: correlation between endometrial dating and integrated progesterone output in clomiphene citrateinduced cycles. Am J Obstet Gynecol 1990; 163:1986–1991.

    PubMed  CAS  Google Scholar 

  94. Lamb EJ, Colliflower WW, Williams JW. Endometrial histology and conception rates after clomiphene citrate. Obstet Gynecol 1972; 39:389–396.

    PubMed  CAS  Google Scholar 

  95. Benda JA. Clomiphene’s effect on endometrium in infertility. Int J Gynecol Pathol 1992; 11:273–282.

    Article  PubMed  CAS  Google Scholar 

  96. Birkenfeld A, Navot D, Levij IS, Laufer N, Beier-Hellwig K, Goecke C, et al. Advanced secretory changes in the proliferative human endometrial epithelium following clomiphene citrate treatment. Fertil Steril 1986; 45:462–468.

    PubMed  CAS  Google Scholar 

  97. Thatcher SS, Donachie KM, Glasier A, Hillier SG, Baird DT. The effects of clomiphene citrate on the histology of human endometrium in regularly cycling women undergoing in vitro fertilization. Fertil Steril 1988; 49:296–301.

    PubMed  CAS  Google Scholar 

  98. Li TC, Warren MA, Murphy C, Sargeant S, Cooke ID. A prospective, randomised, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal, fertile women. Br J Obstet Gynaecol 1992; 99:1008–1013.

    PubMed  CAS  Google Scholar 

  99. Floyd WS. Danazol: Endocrine and endometrial effects. Int J Fertil 1980; 25:75–80.

    PubMed  CAS  Google Scholar 

  100. Fedele L, Marchini M, Bianchi S, Baglioni A, Bocciolone L, Nava S. Endometrial patterns during danazol and buserelin therapy for endometriosis: Comparative structural and ultrastructural study. Obstet Gynecol 1990; 76:79–84.

    PubMed  CAS  Google Scholar 

  101. Beaumont H, Augood C, Duckitt K, Lethaby A. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev 2002;(2):CD001017.

    Google Scholar 

  102. Robins JC. Therapies for the treatment of abnormal uterine bleeding. Curr Womens Hlth Rep 2001; 1:196–201.

    CAS  Google Scholar 

  103. Soh E, Sato K. Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women. Cancer 1990; 66:983–988.

    Article  PubMed  CAS  Google Scholar 

  104. Tamaoka Y, Orikasa H, Sumi Y, Sakakura K, Kamei K, Nagatani M, et al. Direct effect of danazol on endometrial hyperplasia in adenomyotic women: Treatment with danazol containing intrauterine device. Hum Cell 2000; 13:127–133.

    PubMed  CAS  Google Scholar 

  105. Wentz AC, Jones GS, Sapp KC, King TM. Progestational activity of danazol in the human female subject. Am J Obstet Gynecol 1976; 126:378–384.

    PubMed  CAS  Google Scholar 

  106. Marchini M, Fedele L, Bianchi S, Dinola G, Nava S, Vercellini P. Endometrial patterns during therapy with danazol or gestrinone for endometriosis—structural and ultrastructural study. Hum Pathol 1992; 23:51–56.

    Article  PubMed  CAS  Google Scholar 

  107. Jeppsson S, Mellquist P, Rannevik G. Shortterm effects of danazol on endometrial histology. Acta Obstet Gynecol Scand Suppl 1984; 123:41–44.

    Article  PubMed  CAS  Google Scholar 

  108. Fedele L, Bianchi S, Marchini M, Di Nola G. Histological impact of medical therapy—clinical implications. Br J Obstet Gynaecol 1995; 102(Suppl 12):8–11.

    PubMed  CAS  Google Scholar 

  109. Brooks PG, Serden SP, Davos I. Hormonal inhibition of the endometrium for resectoscopic endometrial ablation. Am J Obstet Gynecol 1991; 164:1601–1608.

    PubMed  CAS  Google Scholar 

  110. Reshef E, Segars JH, Hill GA, Pridham DD, Yussman MA, Wentz AC. Endometrial inadequacy after treatment with human menopausal gonadotropin/human chorionic gonadotropin. Fertil Steril 1990; 54:1012–1016.

    PubMed  CAS  Google Scholar 

  111. Bonhoff A, Naether O, Johannisson E, Bohnet HG. Morphometric characteristics of endometrial biopsies after different types of ovarian stimulation for infertility treatment. Fertil Steril 1993; 59:560–566.

    PubMed  CAS  Google Scholar 

  112. Campbell BF, Phipps WR, Nagel TC. Endometrial biopsies during treatment with subcutaneous pulsatile gonadotrophin releasing hormone and luteal phase human chorionic gonadotropins. Int J Fertil 1988; 33:329.

    PubMed  CAS  Google Scholar 

  113. Sterzik K, Dallenbach C, Schneider V, Sasse V, Dallenbach-Hellweg G. In vitro fertilization: The degree of endometrial insufficiency varies with the type of ovarian stimulation. Fertil Steril 1988; 50:457–462.

    PubMed  CAS  Google Scholar 

  114. Garcia JE, Acosta AA, Hsiu J-G, Jones HWJ. Advanced endometrial maturation after ovulation induction with human menopausal gonadotropin/human chorionic gonadotropin for in vitro fertilization. Fertil Steril 1984; 41:31–35.

    PubMed  CAS  Google Scholar 

  115. Sharma V, Whitehead M, Mason B, Pryse-Davies J, Ryder T, Dowsett M, et al. Influence of superovulation on endometrial and embryonic development. Fertil Steril 1990; 53:822–829.

    PubMed  CAS  Google Scholar 

  116. Casper RF. Clinical uses of gonadotropin-releasing hormone analogues. Can Med Assoc J 1991; 144:153–158.

    CAS  Google Scholar 

  117. Lemay A, Jean C, Faure N. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach. Fertil Steril 1987; 48:775–782.

    PubMed  CAS  Google Scholar 

  118. Spitz IM, Bardin CW. Mifepristone (RU 486)—a modulator of progestin and glucocorticoid action. N Engl J Med 1993; 329:404–412.

    Article  PubMed  CAS  Google Scholar 

  119. Swahn ML, Bygdeman M, Cekan S, Xing S, Masironi B, Johannisson E. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium. Hum Reprod 1990; 5:402–408.

    PubMed  CAS  Google Scholar 

  120. Li T-C, Dockery P, Thomas P, Rogers AW, Lenton EA, Cooke ID. The effects of progesterone receptor blockade in the luteal phase of normal fertile women. Fertil Steril 1988; 50:732–742.

    PubMed  CAS  Google Scholar 

  121. Batista MC, Cartledge TP, Zellmer AW, Merino MJ, Axiotis C, Loriaux DL, et al. Delayed endometrial maturation induced by daily administration of the antiprogestin RU-486—A potential new contraceptive strategy. Am J Obstet Gynecol 1992; 167:60–65.

    PubMed  CAS  Google Scholar 

  122. Cameron ST, Critchley HO, Thong KJ, Buckley CH, Williams AR, Baird DT. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum Reprod 1996; 11:2518–2526.

    PubMed  CAS  Google Scholar 

  123. Heikinheimo O, Hsiu JG, Gordon K, Kim S, Williams RF, Gibbons WE, et al. Endometrial effects of RU486 in primates—antiproliferative action despite signs of estrogen action and increased cyclin-B expression. J Steroid Biochem Mol Biol 1996; 59:179–190.

    Article  PubMed  CAS  Google Scholar 

  124. Gemzell-Danielsson K, Westlund P, Johannisson E, Swahn ML, Bygdeman M, Seppala M. Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum Reprod 1996; 11:256–264.

    PubMed  CAS  Google Scholar 

  125. Jimenez-Moreno V, Billeter M, Liu CQ, Gordon K, Mahony M. Local effects of mifepristone on the nonhuman primate endometrium. Fertil Steril 2000; 74:134–140.

    Article  PubMed  CAS  Google Scholar 

  126. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003; 18:61–68.

    Article  PubMed  CAS  Google Scholar 

  127. Croxatto HB, Kovacs L, Massai R, Resch BA, Fuentealba B, Salvatierra AM, et al. Effects of long-term low-dose mifepristone on reproductive function in women. Hum Reprod 1998; 13:793–798.

    Article  PubMed  CAS  Google Scholar 

  128. Greb RR, Kiesel L, Selbmann AK, Wehrmann M, Hodgen GD, Goodman AL, et al. Disparate actions of mifepristone (RU 486) on glands and stroma in the primate endometrium. Hum Reprod 1999; 14:198–206.

    Article  PubMed  CAS  Google Scholar 

  129. Murphy AA, Kettel LM, Morales AJ, Roberts V, Parmley T, Yen SS. Endometrial effects of long-term low-dose administration of RU486. Fertil Steril 1995; 63:761–766.

    PubMed  CAS  Google Scholar 

  130. Newfield RS, Spitz IM, Isacson C, New MI. Long-term mifepristone (RU 486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf) 2001; 54:399–404.

    Article  CAS  Google Scholar 

  131. Koering MJ, Healy DL, Hodgen GD. Morphologic response of endometrium to a progesterone receptor antagonist, RU486, in monkeys. Fertil Steril 1986; 45:280–287.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Upstate Medical University, State University of New York, Syracuse, NY 13210

    Michael T. Mazur MD (Clinical Professor of Pathology)

  2. ClearPath Diagnostics, Syracuse, NY 13202, USA

    Michael T. Mazur MD (Clinical Professor of Pathology)

  3. Departments of Gynecology, Obstetrics and Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231, USA

    Robert J. Kurman MD (Richard W. TeLinde, Distinguished Professor)

  4. The Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA

    Robert J. Kurman MD (Richard W. TeLinde, Distinguished Professor)

Authors
  1. Michael T. Mazur MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert J. Kurman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Mazur, M.T., Kurman, R.J. (2005). Effects of Hormones. In: Diagnosis of Endometrial Biopsies and Curettings. Springer, New York, NY. https://doi.org/10.1007/978-0-387-26321-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-26321-2_6

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-98615-9

  • Online ISBN: 978-0-387-26321-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation